Nine Chapters Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nine Chapters Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-19,600	Closed	-$2.06M	–	80
2015 Q3	$2.06M	Buy	+19,600	New	+$2.62M	0.18%	155
2013 Q4	–	Sell	-3,000	Closed	-$217K	–	792
2013 Q3	$217K	Sell	3,000 -4,000	-57%	-$266K	0.03%	617
2013 Q2	$390K	Buy	+7,000	New	+$436K	0.07%	398

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nine Chapters Capital Management's BMRN Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 19,600 shares — an estimated $2.06M sold.

Nine Chapters Capital Management first reported a position in BMRN in Q2 2013 and held it in 3 quarters. The position peaked at $2.06M in Q3 2015. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

Nine Chapters Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 19,600 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $2.06M.
Nine Chapters Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Nine Chapters Capital Management's BioMarin Pharmaceuticals position peaked at $2.06M in Q3 2015.
388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.